🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Recruitingn/aAges 18 Years - anyAllMethodist Health System
NCT04090034 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. \> 18 years of age 2. Diagnosed with gastroenteropancreatic primary NET and has consented to undergo PRRT per the treating physician. Specifically: * Will consider other primaries on a case by case basis if dotatate scan (+) and meet all other criteria. * Metastatic or Locally Advanced AND Inoperable * Clear disease progression on Octreotide over less than 3 years (RECIST 1.1) * Presence of disease within 24 weeks as identified by PET/CT scans with Ga-68 DOTATATE reporting the Krenning score for low-grade NET and/or PET/CT scans with FDG for transformation to high-grade NET * Well differentiated on path - Ki67 \< 20% * Octreotide positive on pathology (if not documented, acceptable if PET/CT imaging shows lesions with Ga-68 DOTATATE uptakeLabs: * Cr. \<1.7 * Hgb \>8 * WBC \>2K * Plt \>75K * Bili \< 3x normal limit * No Octreotide within 30 days of administration. 3. Willing and able to comply with the protocol requirements 4. Able to comprehend and sign the Informed Consent Form in English. Exclusion Criteria: * Do not meet the Study Inclusion Criteria laid out in section 6.3
💊

What it tests

  • Peptide Receptor Radionuclide Therapy
📍

Where

2 sites
Clinical Research Institute at Methodist Health System
Dallas, United States
Methodist Dallas Medical Center
Dallas, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy